NewsSource: EClinCloud official website historical archive

36Kr Exclusive | Building a Clinical Evidence Support SaaS Cloud Platform: EClinCloud Raises Tens of Millions of RMB in Series A Financing

4 min readEClinCloud Editorial Team
Archived article cover: First on 36Kr | Building a Clinical Evidence Support SaaS Cloud Platform, EClinCloud Raises Tens of Millions of Yuan in Series A Financing
In China, electronic clinical outcome assessment (eCOA) systems remain a blue ocean.

36Kr has learned that EClinCloud, a clinical-research SaaS cloud platform, recently completed a Series A financing round of tens of millions of RMB, exclusively invested by Kangjun Capital. The funding will be used for platform R&D, building clinical operations and data science teams, after-sales service and operations and maintenance, and related areas, to accelerate the realization of a "patient-centric" integrated cloud platform and provide clinical trial endpoint assessment solutions.

To date, the clinical evidence support cloud platform initially built by EClinCloud includes electronic clinical outcome assessment (eCOA), clinical trial management system (CTMS), electronic trial master file (eTMF), electronic data capture (EDC), and randomization and trial supply management (RTSM), among others. Using digital technology to enable new drug R&D, it serves clients including pharmaceutical companies, medical device companies, and research institutions.

临床试验项目计划、执行与收尾的一体化系统图

Electronic systems applicable to intelligent clinical research. Source: "Expert Consensus on Intelligent Clinical Research" (智能化临床研究专家共识)

Currently, in China's digital clinical research industry, competition in electronic data capture systems is relatively intense, whereas electronic clinical outcome assessment (eCOA) systems remain a blue ocean. eCOA refers to tools that electronically describe how a patient feels, functions, or survives in a clinical trial.

Clinical endpoint assessment for diseases such as neurological disorders and oncology often involves completing qualitative assessment scales, requiring high consistency in data collection. EClinCloud's eCOA system provides an extensive library of standard scales and supports complex logic checks, using relationships between items across scales to support raters in identifying data anomalies. In addition, sponsors, CROs, and study sites can all access and view data in real time through reporting tools across different dimensions.

Currently, EClinCloud's team consists primarily of R&D personnel. CEO Dr. Qin Long graduated from Beihang University and conducted postdoctoral research in medical statistics at Sun Yat-sen University. He previously served as Sales Manager at Oracle, Regional Sales Head at Medidata, and Head of Asia-Pacific at Signant Health; with 15 years in clinical trial research, he has a deep understanding of both technology and the market. Before joining EClinCloud, CTO Wu Weiping served as China CTO at Hitachi Vantara (Hitachi's data management company), and is an entrepreneur with expertise in infrastructure, SaaS, data storage, and security.

In terms of commercialization, EClinCloud has established partnerships with multiple domestic innovative pharmaceutical companies and CROs; leveraging the founding team's channel resources, it will continue to expand in the market through direct sales and distribution.

In addition, EClinCloud has become the exclusive operating representative in Greater China for Signant Health, an international clinical evidence support company, promoting eCOA software and services according to client needs. Headquartered in the United States, Signant Health focuses on clinical research in neurology and oncology; its eCOA solutions have been used in nearly 2000 clinical trials globally, serving more than 900 organizations and covering approximately 960,000 patients.

With support from international experts, EClinCloud will also expand its business in scale services, back-end medical support, rater training, and endpoint assessment for multi-center clinical trials. EClinCloud CEO Qin Long noted, "High-quality platform products and high-value-added services are the foundation of EClinCloud's development."

Taking the Clinical Trial Management System (CTMS) as an example, EClinCloud CTMS features a user interface configurable to client needs, preset milestone event management, monitoring visit workflows with built-in monitoring report templates, and role-based alerts to improve monitor efficiency; in terms of data extensibility, it can integrate with upstream and downstream systems to avoid duplicate entry and support multi-center clinical trials.

On November 20, the national Center for Drug Evaluation (CDE) officially issued the "Guiding Principles for Clinical Value-Oriented Clinical Development of Antitumor Drugs." "Clinical outcome assessment (COA) that reflects clinical significance and value" appears in the first paragraph, specifically noting that it "encourages applicants to reference or develop multiple assessment methods, such as electronic patient-reported outcomes (ePRO) recorded by electronic means," and encourages applicants to incorporate decentralized clinical trial (DCT) designs to reduce barriers to study participation through remote monitoring and data collection.

According to Frost & Sullivan estimates, China's clinical research IT market reached approximately RMB 3.7 billion in 2019 and is projected to reach RMB 16 billion by 2024. In recent years, domestic and international CROs such as IQVIA, Tigermed, and Fountain Medical Development have all been positioning themselves in clinical trial digitalization; under current data security policies, domestic clinical IT systems hold a considerable advantage.

Source: 36Kr https://36kr.com/p/1507019952410371

Related reading

Archived article cover: With Rising Pharmaceutical Submissions and Tightening Investment, How Can Digital Solutions Help Clinical Research Reduce Costs and Improve Efficiency?News7 min readWith Rising Drug Filings and Tightening Investment, How Can Digital Solutions Help Reduce Costs and Improve Efficiency in Clinical Research?As the biopharmaceutical industry continues to develop, innovative drug R&D has entered a period of rapid growth, and the number of clinical drug trials is trending upward. Alongside this, improving clinical trial efficiency and reducing the costs and risks of clinical research have become urgent priorities for a growing number of pharmaceutical companies and research institutions. Using digital tools to advance the digital and intelligent development of clinical trials is undeniably the prevailing trend. To better meet the needs of digital and intelligent clinical development and share the latest achievements and solutions, EClinCloud recently convened in Chengdu its first User Conference, "Digital and Intelligent Empowerment: Symbiosis and Win-Win," bringing together pharmaceutical industry leaders for discussions.Article cover for "Scale scoring: a different score from every rater? An overview of the history of neuropsychological scale assessment"News8 min readInconsistent Scale Scoring? Understanding Neuropsychological Scale AssessmentIn neurology, neuropsychological assessment is an indispensable tool in clinical diagnosis and research. However, during clinical scale assessments, raters may apply varying degrees of subjective judgment and interpret the scales inconsistently, leading to differences in scoring outcomes; if a rater uses leading language or questions during the assessment, this can also introduce bias into the results. In the field of neuropsychology in particular, neuropsychological assessment results often serve as the primary endpoint of clinical trials; biased results may reduce a clinical trial's reliability and, in severe cases, lead to study failure. Therefore, standardized training on the use of neuropsychological assessment scales is necessary to...Archived article cover: EClinCloud eCOA system passes CFDI inspection, supporting marketing approval of Raynovent's COVID-19 treatment leritrelvir tabletsNews4 min readEClinCloud eCOA System Passes CFDI Inspection, Supporting Marketing Approval of Raynovent's COVID-19 Treatment Leritrelvir TabletsOn March 23, 2023, in accordance with the relevant provisions of the Drug Administration Law and under the special drug approval procedures, the National Medical Products Administration (NMPA) granted conditional marketing approval to leritrelvir tablets (brand name: Leruiling), a Category 1 innovative drug submitted by Guangdong Raynovent Biotech Co., Ltd. (hereinafter referred to as "Raynovent"). The drug is an oral small-molecule therapy for novel coronavirus infection, indicated for the treatment of adult patients with mild-to-moderate novel coronavirus infection (COVID-19).